STAT+: Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B
LONDON — The French pharma company Servier said Friday that it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion. Servier, which is privately held, is paying $21.50 a share in cash for Day One, a roug...
🔗 Read more: https://www.statnews.com/2026/03/06/servier-dayone-pediatric-cancer/?utm_campaign=rss
#News #Medicine #Biotech #Tech #Neuro #Psychology #Science
Edited
www.statnews.com
STAT+: Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B
LONDON — The French pharma company Servier said Friday that it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion. Servier, which is privately held, is paying $21.50 a share in cash for Day One, a roughly 68% premium on the...
Comments
Log in to leave a comment.
No comments yet. Be the first to comment!